Abstract
Hypertensive disorders in pregnancy (HDPs) significantly contribute to maternal and fetal complications, particularly in adolescent pregnancies. This study examines the prevalence and predictors of gestational hypertension (gHTN) among U.S. adolescents between 2016 and 2022, using data from the CDC’s Birth Data Files. The analysis included various maternal factors, such as age, race, education, BMI, prenatal care, and participation in the Women, Infants, and Children (WIC) Nutritional Program. Logistic Regression and Random Forest models were employed to evaluate these predictors, with Random Forest showing superior predictive performance. The study found that gHTN prevalence increased from 6.72% in 2016 to 9.51% in 2022, with BMI, month prenatal visits began, WIC participation, and race emerging as key predictors. The findings highlight the importance of early prenatal care and targeted support for adolescents to manage gHTN, emphasizing the need for interventions that address modifiable risk factors such as BMI and access to nutritional programs. This research underscores the critical need for continued efforts to mitigate the rising trend of gHTN in adolescent pregnancies and improve maternal and fetal outcomes in this vulnerable population. Future studies should focus on identifying additional predictors and tailoring interventions to meet the unique needs of adolescent mothers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this work. The authors and their institutions did not receive any payment or services from a third party for any aspect of the submitted work, including study design, data collection, statistical analysis, manuscript preparation, or any other components.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has IRB approval by the University of Houston.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available in the CDC's Vital Statistics Online Data Repository at https://www.cdc.gov/nchs/data_access/VitalStatsOnline.htm#Births. These data were derived from the following public domain resources: the CDC's Birth Data Files, accessible through the National Center for Health Statistics (NCHS).
